ライフサイエンスコーパス: angiogenic factor

1 ain 7 (EGFL7), an extracellular matrix-bound angiogenic factor.

2 l growth factor (VEGF) is the most important angiogenic factor.

3 n (FMOD), which we determined to be a potent angiogenic factor.

4 porting Netrin-4 as either a pro- or an anti-angiogenic factor.

5 ional vessel development, acting as a potent angiogenic factor.

6 ion, uptake, and decay of tumor-secreted pro-angiogenic factor.

7 pel-Trenaunay syndrome (KTS), and encodes an angiogenic factor.

8 erular endotheliosis, and production of anti-angiogenic factors.

9 ted with downregulation of several important angiogenic factors.

10 nherently express and secrete high levels of angiogenic factors.

11 suppresses decidualization and misregulates angiogenic factors.

12 , metastases, secretion of cytokines and pro-angiogenic factors.

13 iple inflammatory cytokines, chemokines, and angiogenic factors.

14 iated accumulation of HIF-1alpha and related angiogenic factors.

15 pondin-1 (TSP-1) and its receptor CD36, anti-angiogenic factors.

16 ocess is further triggered by the release of angiogenic factors.

17 developing vessel networks exposed to excess angiogenic factors.

18 as chaperones, hormone transporters, or anti-angiogenic factors.

19 al protein synthesis, and down-regulation of angiogenic factors.

20 d to upregulation of NF-kappaB-derived tumor angiogenic factors.

21 matory cells, cytokines, growth factors, and angiogenic factors.

22 ioscaffolds or bioscaffolds not treated with angiogenic factors.

23 p-regulating production of Th2 cytokines and angiogenic factors.

24 on of several cytokines, growth factors, and angiogenic factors.

25 kappaB and several cytokines, and growth and angiogenic factors.

26 real-time PCR, and Western blot analysis of angiogenic factors.

27 thmatic airways via modulating pro- and anti-angiogenic factors.

28 he imbalance between pro-angiogenic and anti-angiogenic factors.

29 ing their secretion of various pro- and anti-angiogenic factors.

30 promoting the highest increases in EPCs and angiogenic factors.

31 g and is mediated by a plethora of potential angiogenic factors.

32 e biological processes that are regulated by angiogenic factors.

33 ascular repair by paracrine secretion of pro-angiogenic factors.

34 nes, as well as genes encoding receptors for angiogenic factors.

35 proteins, granulation tissue components, and angiogenic factors.

36 ealed that IL1R2 activates the expression of angiogenic factors.

37 rowth and metastasis and is dependent on key angiogenic factors.

38 gulated by the balance between pro- and anti-angiogenic factors.

39 Placental growth factor (PlGF) is an angiogenic factor, a secondary marker of associated plac

40 tokine IL-8 and increased levels of the anti-angiogenic factors activin-A and pigment epithelium-deri

41 proliferation, migration, and expression of angiogenic factors, additional factors and environmental

42 e fibroblast growth factor (FGF) is a potent angiogenic factor and aberrant FGF signaling is a common

43 uidance molecule Slit3 is a novel and potent angiogenic factor and functions to promote angiogenesis

44 growth factor (VEGF) is the most potent pro-angiogenic factor and is regulated by pathways related t

45 helial growth factor (VEGF) is a predominant angiogenic factor and its dosage is precisely regulated

46 results demonstrate that NPNT is a paracrine angiogenic factor and may play a role in pathological os

47 val and transformation, IL-8 functions as an angiogenic factor and pro-survival signal, and ICAM-1 ha

48 in glucose transporters, glycolytic enzymes, angiogenic factors and cardiac morphology were examined

49 adhesion, and the autocrine release of some angiogenic factors and extracellular matrix components.

50 dysfunctional with respect to the release of angiogenic factors and functions including thrombosis, a

51 Using this model, we screened the effects of angiogenic factors and identified two distinct cocktails

52 by simultaneously down-regulating potent pro-angiogenic factors and inducing endogenous anti-angiogen

53 imited because of insufficient expression of angiogenic factors and low cell viability after transpla

54 eatment, and then, we assessed expression of angiogenic factors and mechanotransducers (focal adhesio

55 associated with elevated renal expression of angiogenic factors and mechanotransducers, particularly

56 ssion of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular end

57 diators of vascular response, including both angiogenic factors and small molecules such as nitric ox

58 Plasma angiogenic factors and VEGFR2 phosphorylation in mononuc

59 etion of multiple cytokines, chemokines, and angiogenic factors and, in particular, with the inductio

60 m is to act as a "survival," rather than an "angiogenic" factor and that VEGF-B inhibition may offer

61 AGGF1 is an angiogenic factor, and its deregulation is associated wi

62 s, inflammatory cells, cytokines, growth and angiogenic factors, and angiogenesis.

63 s a constitutive network of other cytokines, angiogenic factors, and chemokines that may act in an au

64 Erythropoietin (EPO) is one of the systemic angiogenic factors, and its role in ocular angiogenesis

65 ells, vascular endothelial cells, diffusible angiogenic factors, and necrosis formation into a first-

66 terplay among hypoxic Muller cells, secreted angiogenic factors, and neighboring ECs in the regulatio

67 iators, including growth factors, cytokines, angiogenic factors, and other mitogenic pathways.

68 te accumulation, downregulation of pulmonary angiogenic factors, and reduced symptoms of HPS.

69 l growth factors, cytokines, chemokines, and angiogenic factors, and the multifunctional angiogenic p

70 ction of miR-221 and subsequent induction of angiogenic factors Angiogenin and CXCL16.

71 tly target and repress the mRNA encoding the angiogenic factor angiopoietin 1 (ANGPT1), leading to de

72 We hypothesized that deregulation of an angiogenic factor, angiopoietin-2 (Ang-2), in patients w

73 etinas identified an increase in the key pro-angiogenic factor, angiopoietin-2, as the most significa

74 ncluding a reset profile of pro- versus anti-angiogenic factors, apparently distinct for physiologica

75 howed that vascularization and expression of angiogenic factors are evident in the colonic mucosa of

76 Complementary angiogenic factors are therefore regulated by the subcel

77 pression of transcripts for neurotrophic and angiogenic factors, as well as JUN, all of which are ess

78 ocked the overexpression of the inflammatory/angiogenic factors, attenuated leukostasis, and reduced

79 tant regulator of the expression of multiple angiogenic factors, bevacizumab-initiated up-regulation

80 Signaling pathways engaged by angiogenic factors bFGF and VEGF in tumor angiogenesis a

81 3D cultures in expression of most canonical angiogenic factors but suggested changes in several path

82 d by a balance between positive and negative angiogenic factors, but temporal protein expression of m

83 lue light filtering affects the secretion of angiogenic factors by retinal pigmented epithelial cells

84 conducted a broad profiling of cytokine and angiogenic factors (CAF) to investigate the relationship

85 duce changes in these or other cytokines and angiogenic factors (CAFs) and whether such changes could

86 ges during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatm

87 atment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a

88 We found that expression of the angiogenic factor CCN1 was increased in the colons of pa

89 In addition, HIMF-induced production of angiogenic factors/chemokines, such as vascular endothel

90 In line with increased angiogenic factors, conditioned media from RAB11B-AS1-ov

91 herefore, we hypothesized that a circulating angiogenic factor could predict disease severity and sur

92 tor (Y2R), is an autocrine proliferative and angiogenic factor crucial for maintaining NB tumor growt

93 tion resulted in decreased production of pro-angiogenic factors, CXCL1 and vascular endothelial growt

94 , VEGF-independent, clinically relevant, pro-angiogenic factor, CYR61, that is a transcriptional targ

95 , regulatory T-cell numbers, and circulating angiogenic factors did not predict outcome.

96 ession of anti-apoptotic, pro-oncogenic, and angiogenic factors during tumor progression.

97 rs (e.g. CD31) as well as mRNA expression of angiogenic factors (e.g., Vegfa, Flt1, Klf4).

98 vascular endothelial growth factor and other angiogenic factors (eg, ANG [angiogenin], TIMP1/2 [tissu

99 The angiogenic factor Egfl6 was expressed by the K15- bulge

100 Both angiogenic factors enhanced pulp microvessel density com

101 VEGF-A, a potent vascular permeabilizing and angiogenic factor, exerts much of its angiogenic activit

102 ar endothelial growth factor (VEGF) is a key angiogenic factor expressed under restricted nutrient an

103 sue vascularity, possibly reflecting altered angiogenic factor expression in infected cells.

104 ween maternal periodontal disease and plasma angiogenic factor expression of soluble fms-like tyrosin

105 Angiogenesis and angiogenic factor expression were measured by immunohist

106 ern blot of infected cultured cells measured angiogenic factor expression.

107 egulation of visual cycle genes, and altered angiogenic factor expression.

108 ollateral vessel formation and inhibition of angiogenic factors expression and actions.

109 lls lacking Flvcr2 had altered expression of angiogenic factors, failed to adopt tip cell properties,

110 aranase activity releases growth factors and angiogenic factors from heparan sulfate (HS) storage sit

111 ogenesis; they also stimulated production of angiogenic factors from HIMEC and HIF, and HIF-derived a

112 activation induces the secretion of several angiogenic factors from ovarian carcinoma cells, most pr

113 lation of differentially mediated release of angiogenic factors from platelets may provide a new moda

114 RBPJ controls angiogenic factor gene expression independently of Notch

115 tions show: 1), different tumor-secreted pro-angiogenic factor gradient profiles dramatically affect

116 The overexpression of the angiogenic factors has been demonstrated in HCC.

117 Delivery of pro-angiogenic factors has shown some benefit, but it is dif

118 s prospective cohort studies have shown that angiogenic factors have a high diagnostic accuracy in wo

119 of angiogenesis in various diseases and many angiogenic factors have been discovered as therapeutic t

120 antivascular therapies that primarily target angiogenic factors have faced difficulties and failures

121 PlGF emerged as the most efficient and safe angiogenic factor, hence making it a candidate for thera

122 Placental growth factor (PlGF) is an angiogenic factor identified in the maternal circulation

123 on of angiopoietin-like 4 (ANGPTL4), a known angiogenic factor in cancer, in tumors from obese mice.

124 of stem cell factor (SCF), an important pro-angiogenic factor in GBM.

125 IL-32 could function as an inflammatory and angiogenic factor in human obesity and obesity-associate

126 r endothelial growth factor-A mRNA, a potent angiogenic factor in the settings of tumor development a

127 ar endothelial growth factor (VEGF) is a key angiogenic factor in tumors, but less is known about wha

128 however, by the current inability to deliver angiogenic factors in a sustained manner at the site of

129 In the absence of prematurity, UPI increased angiogenic factors in association with reduced OIR sever

130 tor signaling linked to up-regulation of pro-angiogenic factors in cardiac Sca-1(+)CD31(-) stromal ce

131 ct the biological activity driven by the two angiogenic factors in endothelial cells, as evidenced by

132 We aimed to evaluate the expression of angiogenic factors in hepatitis C virus (HCV)-HCC tissue

133 nge of chemokines, cytokines, and growth and angiogenic factors in MAPK inhibitor-treated metastatic

134 -mutated MDSCs significantly secrete various angiogenic factors in MDSCs regardless of hypoxia or nor

135 y mechanotransduction-mediated expression of angiogenic factors in proximal tubular cells, and it may

136 or the HDM2 oncoprotein in the regulation of angiogenic factors in renal cell carcinoma.

137 xpression of several pro-angiogenic and anti-angiogenic factors in response to (1) a single acute bou

138 Temporal expression of positive and negative angiogenic factors in response to detraining is poorly u

139 To examine the role of angiogenic factors in the coordinated development of isl

140 ate that there is an increased expression of angiogenic factors in the liver in different mouse model

141 sm that induces the expression of growth and angiogenic factors in tumors, leading to their local inc

142 a opioid receptor (KOR) agonists act as anti-angiogenic factors in tumors.

143 n block the autocrine and paracrine loops of angiogenic factors in vascular endothelial and cancer ce

144 e progenitors proliferate in response to pro-angiogenic factors, in association with expanding capill

145 Protein and mRNA abundance of several angiogenic factors including CXCL1, VEGF, and IL-8 are d

146 Angiogenic factors including phospho-Akt, phospho-eNOS,

147 nt also did not change retinal expression of angiogenic factors including vascular endothelial growth

148 RAB11B-AS1 enhanced the expression of angiogenic factors including VEGFA and ANGPTL4 in hypoxi

149 ctors, such as endostatin, and decreased pro-angiogenic factors, including CXC motif ligand 1 (CXCL1)

150 HIF-2alpha-dependent expression of specific angiogenic factors, including delta-like ligand 4 (Dll4)

151 cells and impaired production of several key angiogenic factors, including the vascular endothelial g

152 on of angiogenesis and upregulation of other angiogenic factors, including vascular endothelial growt

153 stimulation also induced a broad program of angiogenic factors, including vascular endothelial growt

154 Further, the production of angiogenic factors, including vascular endothelial growt

155 progression, and they involve the release of angiogenic factors, including vascular endothelial growt

156 tube formation assay via Stat3 induction of angiogenic factors, including VEGF and bFGF.

157 imulated GPR81 Muller cells produce numerous angiogenic factors, including Wnt ligands and particular

158 Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine

159 duction, microRNA-210 can upregulate several angiogenic factors, inhibit caspase activity, and preven

160 ration of placental growth factor (PlGF), an angiogenic factor, integrated with a clinical management

161 ficantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma spe

162 elease of proinflammatory cytokines and anti-angiogenic factors into the maternal circulation.

163 closely associated with liver fibrosis, the angiogenic factors involved in liver fibrosis are not we

164 We show that regulation of these angiogenic factors is dependent on ERK1/2 phosphorylatio

165 endothelial growth factor-A (VEGF), a potent angiogenic factor, is also implicated in self-renewal in

166 VEGF-A, an angiogenic factor, is increased in the peritoneal fluid

167 monstrate that empowerment of uNK cells with angiogenic factors keeps them noncytotoxic.

168 r endothelial growth factor (VEGF) and other angiogenic factors, leading to neovascularization and pr

169 Transient increases in angiogenic factor levels and prolonged hyperemia charact

170 ways involving hypoxia-inducible factors and angiogenic factors like VEGF, oxidative species, and neu

171 ated with beta-LGND2 had lower levels of pro-angiogenic factors, like VEGF and HIF1alpha.

172 wth factor-like growth factor (HB-EGF) is an angiogenic factor mediating radial migration of the deve

173 Soluble angiogenic factors might be useful for monitoring high-r

174 pressed Akr1b7, and maturing cells expressed angiogenic factors necessary for the development of the

175 To examine the effect of angiogenic factors on the disease progression of NASH, a

176 ted the effect of miR200-b, a potential anti-angiogenic factor, on VEGF receptor 2 (VEGFR-2) expressi

177 sia (PE) are primarily driven by excess anti-angiogenic factors originating from the placenta.

178 n endothelial function and the regulation of angiogenic factor pathways important for vascular homeos

179 ting, thereby confirming the hypothesis that angiogenic factors play an early role in the disease pro

180 An imbalance in circulating angiogenic factors plays a central role in the pathogene

181 ether matrix metalloproteinase-9 (MMP-9), an angiogenic factor predominantly produced by osteoclasts

182 s and suggest that topical application of an angiogenic factor prior to replantation might be benefic

183 EGFL7 is a secreted angiogenic factor produced by embryonic endothelial cell

184 rated that placenta growth factor (PlGF), an angiogenic factor produced by erythroid cells, induces h

185 kinetics, and proliferative responses toward angiogenic factors progressively resembled those of HDME

186 d islet development while islet cell-derived angiogenic factors promote EC recruitment and extensive

187 factors from HIMEC and HIF, and HIF-derived angiogenic factors promoted HIMEC proliferation.

188 ar endothelial growth factor-A (VEGF) is the angiogenic factor promoting the pathological neovascular

189 cell fenestration, proliferation, and islet angiogenic factor/receptor expression were unchanged in

190 excess centrosomes, suggesting that multiple angiogenic factors regulate centrosome number.

191 we show that inflammatory cytokines, but not angiogenic factors, regulate delta-catenin expression, a

192 ate gradients of biochemical signals such as angiogenic factors released by tumors into the surroundi

193 ased significantly after PPVL, whereas other angiogenic factors remained unchanged.

194 a modulated a couple key angiogenic and anti-angiogenic factors, resulting in an enhanced anti-angiog

195 CB2, show compromised PDZ with dysregulated angiogenic factors, resulting in the retention of blood

196 Slug (but not Snail) is activated by the pro-angiogenic factor SDF1alpha via its canonical receptor C

197 n, specifically by investigating the role of angiogenic factors secreted by prostate cancer cells whi

198 tation under cyclic stretching, supported by angiogenic factors secreted in response to each stretch

199 The angiogenic factors soluble fms-like tyrosine kinase 1 an

200 EPCs increased renal expression of angiogenic factors, stimulated proliferation and maturat

201 In addition, the angiogenic factors stromal cell-derived factor 1 (SDF-1a

202 e of IL-18 in up-regulating secretion of the angiogenic factors stromal cell-derived factor 1alpha (S

203 ith mechanical strain-dependent induction of angiogenic factors such as CCN1, an immediate-early gene

204 nt upregulation of key proliferation and pro-angiogenic factors such as Pdgfa, Pdgfb and Vegf.

205 angiogenesis, likely by down-regulating pro-angiogenic factors such as vascular endothelial growth f

206 that angiogenesis and the expression of pro-angiogenic factors such as vascular endothelial growth f

207 rmation indicates that the expression of pro-angiogenic factors such as VEGFs and angiogenesis play a

208 enic therapy might implicate alternative pro-angiogenic factors, such as basic fibroblast growth fact

209 hile exhibiting increased expression of anti-angiogenic factors, such as endostatin, and decreased pr

210 1 knockdown downregulated various growth and angiogenic factors, such as HIF1alpha, VEGF and CD31, in

211 However, expression of angiogenic factors, such as vascular endothelial growth

212 trosome number is regulated by signaling via angiogenic factors, such as VEGF.

213 and extracellular matrix as well as soluble angiogenic factors, such as VEGF.

214 n the presence of Vegf and other established angiogenic factors, suggesting either that the levels of

215 induced increased production of most of the angiogenic factors tested (i.e., epidermal growth factor

216 lly, murine endoglin ECD-Fc acted as an anti-angiogenic factor that decreased blood vessel sprouting

217 EGFL7 is a secreted angiogenic factor that is highly conserved in vertebrate

218 Pleiotrophin (PTN) is an angiogenic factor that is produced by many different hum

219 cular endothelial growth factor (VEGF) is an angiogenic factor that play important roles in the nervo

220 ANG is the only human angiogenic factor that possesses ribonucleolytic activit

221 factor (VEGF) is recognized as an important angiogenic factor that promotes angiogenesis in a series

222 The VEGF-angiopoietin-1 chimera is a potent angiogenic factor that triggers a novel mode of VEGF rec

223 lastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells,

224 However, data regarding specific angiogenic factors that are secreted within the bone mic

225 retina has been postulated to be a source of angiogenic factors that cause aberrant angiogenesis and

226 related biological functions (p < 0.025) and angiogenic factors that have been associated with recurr

227 Therefore, it is important to identify novel angiogenic factors that play essential roles in tumor an

228 secretory phenotype (SASP) that includes pro-angiogenic factors that promote tumor vascularization, w

229 d intracellular mechanisms downstream of pro-angiogenic factors that regulate sprout formation and in

230 arrow microenvironment secrete cytokines and angiogenic factors that support the maintenance and rege

231 report that histamine and serotonin are also angiogenic factors that, at low micromolar concentration

232 xia inducible factor-1alpha, VEGF, and other angiogenic factors, thereby directly supporting prolifer

233 lthough fibroblast growth factors are potent angiogenic factors, they may indirectly control neovascu

234 evMDSC have increased expression of an anti-angiogenic factor thrombospondin 1 (Tsp-1) and decreased

235 lls is the repression of a key secreted anti-angiogenic factor, thrombospondin-1 (Tsp-1).

236 It acts as an angiogenic factor through multiple mechanisms that inclu

237 esponse in growth, extracellular matrix, and angiogenic factors to mediate the observed morphological

238 cycline activator transgene and a tet-operon-angiogenic factor transgene) to increase the beta cell p

239 c growth factors but increased expression of angiogenic factors, transitioning to a more neurotoxic a

240 5-N,OS(H) binds a variety of heparin-binding angiogenic factors upregulated in PDR vitreous humor bes

241 n of ERK1/2, and decreased expression of the angiogenic factor vascular endothelial growth factor (VE

242 resses transcription of the neurotrophic and angiogenic factor vascular endothelial growth factor (VE

243 rrelated with an increased expression of the angiogenic factor vascular endothelial growth factor (VE

244 e migration-inhibitory factor (MIF), and the angiogenic factor vascular endothelial growth factor (VE

245 ssential for normal vision, and although the angiogenic factor vascular endothelial growth factor A (

246 The transcript of the angiogenic factor vascular endothelial growth factor A (

247 TNF-alpha levels, reduction of the essential angiogenic factor vascular endothelial growth factor, an

248 ntiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (

249 and up-regulates in vitro expression of the angiogenic factor vascular endothelial growth factor.

250 L3), Mip-2 (CXCL2), and MCP-1 (CCL2) and the angiogenic factor vascular endothelial growth factor.

251 dothelial area and in mRNA levels of the pro-angiogenic factors vascular endothelial growth factor an

252 din-1, TSP-1; and endostatin) as well as pro-angiogenic factors (vascular endothelial growth factor,

253 Originally identified as an angiogenic factor, vascular endothelial growth factor (V

254 reased secretion of the HIF-1alpha-regulated angiogenic factor, vascular epidermal growth factor, and

255 and decreased expression of two critical pro-angiogenic factors, vascular endothelial growth factor A

256 in leads to inhibition of COX-2-mediated pro-angiogenic factors, vascular endothelial growth factor,

257 increased concentrations of glucose and the angiogenic factor VEGF as well as higher expression of E

258 cell growth, and decreased the secretion of angiogenic factor VEGF in vitro.

259 au gene upregulate expression of the central angiogenic factor VEGF, which drives abnormal angiogenes

260 The activation of Akt by the potent angiogenic factor VEGF-A does not strongly stabilize mic

261 GATA4 induced the angiogenic factor VEGF-A, directly binding the Vegf-A pr

262 the tumor core and reduced expression of the angiogenic factor VEGF-A.

263 in regulating T cell production of the major angiogenic factor VEGF.

264 corresponding to decreased expression of the angiogenic factor VEGF.

265 PARgamma)-inducible expression of the potent angiogenic factors VEGF-A, apelin, and angiopoietin-like

266 As multiple angiogenic factors (VEGF and basic fibroblast growth fac

267 indirectly by stimulating the production of angiogenic factors (VEGF) by PDL cells.

268 HOXB9 induces the expression of several angiogenic factors (VEGF, bFGF, IL-8, and ANGPTL-2), as

269 treated with growth factors (IGF-1, M-CSF), angiogenic factors (VEGF, IL-8), and matrix proteins fou

270 Although originally identified as an angiogenic factor, VEGF also signals directly to neurons

271 EPO; (2) diminished expression of the potent angiogenic factor, VEGF; and (3) decreased microvascular

272 oxic CAFs by decreasing secretion of the pro-angiogenic factor VEGFA and consequently reducing VEGF/V

273 r up-regulated the protein expression of pro-angiogenic factors VEGFA (vascular endothelial growth fa

274 , miR-15a/16-1 translationally represses pro-angiogenic factors VEGFA, FGF2, and their receptors VEGF

275 within the endocrine pancreas; expression of angiogenic factors was assessed by immunohistochemistry

276 gulating levels of Hif-1alpha, expression of angiogenic factors was decreased in Siah2(-/-) tumors.

277 In all 3 groups a higher expression of the angiogenic factors was encountered in adjacent liver par

278 ormation, gene expression, and production of angiogenic factors was evaluated over time.

279 ial growth factor-A (VEGF-A), the best known angiogenic factor, was originally discovered as a potent

280 By quantifying the levels of host angiogenic factors, we demonstrated that basic fibroblas

281 ficantly up-regulates their secretion of pro-angiogenic factors, we hypothesized that ablation of the

282 Given the role of hypoxia in upregulating angiogenic factors, we hypothesized that the distributio

283 sufficient affinity of the DAF to block both angiogenic factors, we turned to deep mutational scannin

284 Several pazopanib target genes and other angiogenic factors were dysregulated post-treatment.

285 mRNA expression of HIF-1alpha and associated angiogenic factors were evaluated by pimonidazole hydroc

286 Furthermore, 53 angiogenic factors were examined via protein array and c

287 ation, tube formation, and production of pro-angiogenic factors were measured.

288 h4.The regulative effects of TRIM28 on these angiogenic factors were partially mediated by hypoxia-in

289 ents pretreated with bioscaffolds containing angiogenic factors when compared with those who received

290 s point to L1-DeltaTM as a novel, EC-derived angiogenic factor which may represent a target for innov

291 modulate stromal cells to produce growth and angiogenic factors, which in turn provide the tumor with

292 Acute myeloid leukemia (AML) cells produce angiogenic factors, which likely contribute to this remo

293 R, are required for macrophage production of angiogenic factors, which play critical roles in the neo

294 ling axis of p-p38/p-MAPKAPK2, NFkappaB, and angiogenic factors, which were downregulated by HI.

295 ll as several cytokines, growth factors, and angiogenic factors, which were significantly affected by

296 Thrombospondin-1 (TSP-1) is one of the anti-angiogenic factors whose synthesis is driven by hypoxia.

297 AGGF1 is an angiogenic factor with therapeutic potential to treat co

298 As a result, we identified Cyr61, an angiogenic factor with unknown neuronal function, as a n

299 rogels to sequester endogenously synthesized angiogenic factors within the matrix.

300 -induced neovascularization and secretion of angiogenic factors within the tumor microenvironment.